Boehringer Ingelheim has reported new Phase III data for survodutide, its once-weekly dual GLP-1/glucagon receptor agonist for obesity, highlighting reductions in body weight, visceral fat and liver fat. The results, presented at the American Diabetes Association Scientific Sessions, strengthen the company’s case that survodutide could offer a differentiated profile in metabolic disease, although gastrointestinal tolerability remains a key question.
Novo Nordisk has moved a step closer to bringing an oral version of Wegovy to the European obesity market, after the Committee for Medicinal Products for Human Use (CHMP) recommended approval of once-daily oral semaglutide 25 mg for weight management.
Harbour BioMed has published preclinical obesity data on a potential challenger to Eli Lilly’s bimagrumab discovered using its artificial intelligence-enabled platform.
EktaH has shared early clinical trial data on its first-in-class approach to treating obesity, encouraging the biotech to aim to advance the program into Phase 2 in the first half of next year.
Roche and Zealand Pharma have delivered a clinically positive phase 2 readout for petrelintide, their amylin-based obesity drug, but the market reaction made clear that “positive” is no longer enough in the weight-loss race. After the companies reported that patients achieved up to 10.7% mean weight loss at 42 weeks, shares in both partners fell sharply as investors questioned whether the candidate can stand out in an increasingly crowded field.
FDA approves Novo Nordisk’s first oral GLP-1 pill Wegovy for obesity, offering an injection-free option and improving long-term treatment adherence.
Danish Zealand Pharma A/S partners with Chinese start-up OTR Therapeutics Co. Ltd to expand oral obesity pipeline in US$30m upfront deal.
Lilly’s triple weight loss combination therapy retatrutide has shown 28.7% weight loss in Phase 3, but higher discontinuations vs. tirzepatide and semaglutide.
MitoRx Therapeutics Ltd has raised £5.5m in a seed financing to advance Myo‑004, a small molecule mitochondrial-targeted obesity therapy enabling fat loss while preserving lean muscle mass.
AstraZeneca plc acquires SixPeaks Bio Inc to target muscle‑preserving obesity therapies, boosting its pipeline in a US$30 bn fast-growing weight-loss market.
IQVIA
Momoneymoproblemz - wikimedia
MitoRx Therapeutics Ltd
stock.adobe.photos.com - gavi